Overview

Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

Status:
Completed
Trial end date:
2019-03-05
Target enrollment:
Participant gender:
Summary
The investigators aim to analyse in adolescents with mental illness effectiveness, side effects, and serum level concentrations of antipsychotics (olanzapine and aripiprazole), antidepressants (Duloxetine, Atomoxetine) by means of "Therapeutic Drug Monitoring" (TDM) in order to optimize dosage - effect relations and minimize unwanted side effects.
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Aripiprazole
Atomoxetine Hydrochloride
Duloxetine Hydrochloride
Olanzapine